Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1929 1
1947 1
1948 2
1949 2
1950 10
1951 1
1952 9
1953 5
1954 6
1955 10
1956 11
1957 18
1958 19
1959 6
1960 16
1961 20
1962 15
1963 23
1964 9
1965 4
1966 18
1967 19
1968 29
1969 30
1970 21
1971 33
1972 28
1973 23
1974 20
1975 19
1976 20
1977 8
1978 13
1979 11
1980 10
1981 12
1982 11
1983 11
1984 18
1985 13
1986 12
1987 13
1988 10
1989 15
1990 18
1991 24
1992 18
1993 16
1994 18
1995 17
1996 16
1997 14
1998 11
1999 11
2000 13
2001 15
2002 17
2003 20
2004 22
2005 13
2006 19
2007 21
2008 35
2009 41
2010 36
2011 51
2012 60
2013 37
2014 43
2015 37
2016 48
2017 53
2018 60
2019 53
2020 48
2021 62
2022 45
2023 55
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

1,584 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand E, et al. Among authors: merrill jt. Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369798 Free PMC article. Clinical Trial.
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall'Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Quasny H, Roth DA, Stohl W, van Vollenhoven R, Wallace DJ, Petri M. Urowitz MB, et al. Among authors: merrill jt. Arthritis Care Res (Hoboken). 2022 Nov;74(11):1822-1828. doi: 10.1002/acr.24901. Epub 2022 Aug 4. Arthritis Care Res (Hoboken). 2022. PMID: 35439360 Free PMC article. Review.
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study.
Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, Sammaritano L, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Garabet L, Salmon JE. Buyon JP, et al. Among authors: merrill jt. Ann Intern Med. 2015 Aug 4;163(3):153-63. doi: 10.7326/M14-2235. Ann Intern Med. 2015. PMID: 26098843 Free PMC article.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Vital EM, et al. Among authors: merrill jt. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25. Ann Rheum Dis. 2022. PMID: 35338035 Free PMC article. Clinical Trial.
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Merrill JT, Guthridge J, Smith M, June J, Koumpouras F, Machua W, Askanase A, Khosroshahi A, Sheikh SZ, Rathi G, Burington B, Foster P, Matijevic M, Arora S, Wang X, Gao M, Wax S, James JA, Zack DJ. Merrill JT, et al. Arthritis Rheumatol. 2023 Dec;75(12):2185-2194. doi: 10.1002/art.42652. Arthritis Rheumatol. 2023. PMID: 37459248 Clinical Trial.
Reply.
Merrill JT. Merrill JT. Arthritis Rheumatol. 2022 Jun;74(6):1093. doi: 10.1002/art.42096. Epub 2022 Apr 19. Arthritis Rheumatol. 2022. PMID: 35188717 No abstract available.
The frequency and outcome of lupus nephritis: results from an international inception cohort study.
Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V. Hanly JG, et al. Among authors: merrill jt. Rheumatology (Oxford). 2016 Feb;55(2):252-62. doi: 10.1093/rheumatology/kev311. Epub 2015 Sep 5. Rheumatology (Oxford). 2016. PMID: 26342222 Free PMC article.
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D; ADDRESS II Investigators. Merrill JT, et al. Arthritis Rheumatol. 2018 Feb;70(2):266-276. doi: 10.1002/art.40360. Arthritis Rheumatol. 2018. PMID: 29073347 Free PMC article. Clinical Trial.
1,584 results